Connetics Olux adds non-scalp psoriasis
This article was originally published in Pharmaceutical Approvals Monthly
Connetics hopes to significantly expand the market for Olux (clobetasol propionate, 0.05%) with the Dec. 20 approval of the topical corticosteroid foam for short-term treatment of mild to moderate non-scalp psoriasis (excluding the face and intertriginous areas). The company estimates that approximately 80% of all prescriptions for psoriasis are for areas other than the scalp. Olux was previously approved for steroid-responsive scalp dermatose
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.